<DOC>
	<DOCNO>NCT00003604</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill kidney cancer cell . PURPOSE : Phase II trial study effectiveness interleukin-2 treating patient stage III stage IV kidney cancer remove surgery .</brief_summary>
	<brief_title>Interleukin-2 Treating Patients With Stage III Stage IV Kidney Cancer That Has Been Removed With Surgery</brief_title>
	<detailed_description>OBJECTIVES : I . Determine disease free survival overall survival patient resect stage III IV renal cancer treat interleukin-2 . II . Measure degree rebound lymphocytosis generate regimen patient . OUTLINE : This open label study . Patients receive interleukin-2 IV 15-30 minute 3 consecutive day weekly 6 week , follow 2 week rest . Patients receive 2 treatment course , 8 week duration . Patients follow every 6 month death . PROJECTED ACCRUAL : A total 20 patient accrue within 1 2 year .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III IV renal cancer completely resect high risk recurrence , include least one following : Tumor invade adrenal gland perinephric tissue beyond Gerota 's fascia ( T3a ) OR Tumor extend renal vein , vena cava ( T3b ) OR Tumor grossly extend vena cava diaphragm ( T3c ) OR Tumor invade beyond Gerota 's fascia ( T4 ) OR Any lymph node involvement totally resect ( N13 ) OR Completely resect metastasis sit No brain metastases PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin le 3 time upper limit normal ( ULN ) AST ALT less 3 time ULN Renal : Creatinine great 1.9 mg/dL Cardiovascular : No prior myocardial infarction within 6 month No LVEF le 35 % No primary cardiac arrhythmia beyond occasional PVCs No angina No uncontrolled congestive heart failure No cerebrovascular accident Pulmonary : No dyspnea rest requirement supplemental oxygen Oxygen saturation great 90 % patient symptomatic lung disease Other : Not pregnant nursing Negative pregnancy test Fetile patient must use effective contraception Temperatures great 100.5 degree F must occult infection exclude No psychiatric disorder PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent cyclosporine methotrexate Endocrine therapy : At least 3 week since prior corticosteroid No concurrent corticosteroid Radiotherapy : Not specify Surgery : At least 2 week since prior surgery Other : At least 3 week since prior immunosuppressive medication No concurrent immunosuppressive medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>